Insights
Search Results
Client Highlights
12.04.25
Wilson Sonsini Advises Belite Bio on Patent Matters Related to $350 Million Public Offering of American Depositary Shares
On December 1, 2025, Belite Bio, a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, announced the pricing of an underwritten public offering at approximately $350 million. Wilson Sonsini Goodrich & Rosati has advised Belite Bio on patent matters since the company's inception, in addition to FDA regulatory, licensing, and litigation matters, and counseled Belite on patent matters related to this latest offering.
Client Highlights
9.30.25
Wilson Sonsini Advises LuxWall on Patent Matters Related to Partnership with Saint-Gobain Glass
On September 22, 2025, Saint-Gobain Glass, a leader in flat glass for building applications, and LuxWall, the pioneer in transparent insulation technology, announced a strategic partnership to bring INSIOTMnext-generation vacuum glazing to the European market. Wilson Sonsini Goodrich & Rosati created LuxWall’s patent strategy and advised the company on patent matters related to the transaction.
Client Highlights
9.10.25
Firm Advises Belite Bio on Patent Matters Related to $275 Million Private Placement
On September 10, 2025, Belite Bio, Inc., a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, announced that it has entered into securities purchase agreements with leading healthcare investors for a private placement in public equity financing (PIPE) that is expected to result in gross proceeds of approximately $125 million, before deducting placement agent fees and estimated offering expenses, and up to an additional approximately $150 million in gross proceeds if the accompanying warrants are fully exercised for cash. Wilson Sonsini Goodrich and Rosati advised Belite Bio on patent matters related to the transaction.